InventisBio Co., Limited (SHA:688382)
China · Delayed Price · Currency is CNY 19.60
+0.34 (1.77%)
Sep 8, 2026, 4:00 PM EDT
InventisBio Revenue
InventisBio had revenue of 10.78M CNY in the quarter ending June 30, 2026, a decrease of -1.80%. This brings the company's revenue in the last twelve months to 71.44M, down -58.72% year-over-year. In the year 2025, InventisBio had annual revenue of 37.29M, down -77.91%.
Revenue (ttm)
71.44M
Revenue Growth
-58.72%
P/S Ratio
159.00
Revenue / Employee
374.06K
Employees
182
Market Cap
11.36B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 37.29M | -131.50M | -77.91% |
| Dec 31, 2024 | 168.79M | -16.74M | -9.02% |
| Dec 31, 2023 | 185.53M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.19B |
| Tibet Cheezheng Tibetan Medicine | 2.22B |
| Inner Mongolia Furui Medical Science | 1.64B |
| Nanjing Vazyme Biotech | 1.47B |
| Shanghai Medicilon | 1.38B |
| Hualan Biological Vaccine | 1.19B |
| GemPharmatech | 878.13M |
| Mabwell (Shanghai) Bioscience | 873.99M |